Fidelity Investments
APRE icon

Fidelity Investments’s Aprea Therapeutics APRE Stock Holding History

Fidelity Investments’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-501
Closed -$852 – 5374
2025
Q2 		$852 Buy
+501
New +$854 ﹤0.01% 4980
2024
Q2 		– Sell
-161
Closed -$1.08K – 5355
2024
Q1 		$1.08K Buy
+161
New +$1K ﹤0.01% 4774
2022
Q1 		– Sell
-10
Closed -$1K – 4921
2021
Q4 		$1K Buy
+10
New +$883 ﹤0.01% 4086
2021
Q1 		– Sell
-63,064
Closed -$6.21M – 3952
2020
Q4 		$6.21M Sell
63,064
-94,933
-60% -$45.1M ﹤0.01% 2121
2020
Q3 		$76M Buy
157,997
+87
+0.1% +$48.7K 0.01% 1046
2020
Q2 		$122M Buy
157,910
+6,587
+4% +$4.32M 0.01% 803
2020
Q1 		$105M Buy
151,323
+44,202
+41% +$32.4M 0.01% 735
2019
Q4 		$98.3M Buy
+107,121
New +$59M 0.01% 917

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Fidelity Investments's APRE Position: Q3 2025 in Review

Fidelity Investments sold out of Aprea Therapeutics (APRE) in Q3 2025, closing a stake of 501 shares — an estimated $852 sold.

Fidelity Investments first reported a position in APRE in Q4 2019 and held it in 8 quarters. The position peaked at $122M in Q2 2020. 23 funds tracked by Wall St. Rank hold APRE as of Q3 2025.

  • Fidelity Investments reported no remaining Aprea Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 501 Aprea Therapeutics shares in Q3 2025, an estimated $852.
  • Fidelity Investments first reported a position in Aprea Therapeutics in Q4 2019 and held it in 8 quarters.
  • Fidelity Investments's Aprea Therapeutics position peaked at $122M in Q2 2020.
  • 23 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.